Tag

chronic urticaria archivos - Bilastina

Efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases: an exploratory study

Efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases: an exploratory study

By | Eprint, New

Esther Serra, Cristina Campo, Zoltan Novak, Bernadetta Majorek-Olechowska, Grazyna Pulka, Aintzane García-Bea and Luis Labeaga

Pruritus is a common symptom associated with different skin diseases, including urticaria, atopic dermatitis, eczema and prurigo. Pruritus may have a significant impact on the quality of life and psychosocial wellbeing of patients with skin urticaria. Bilastine is a H1-antihistamine with demonstrable efficacy for the symptomatic treatment of chronic spontaneous urticaria.

 

A phase IV, multicentre, open-label, exploratory study to evaluate the efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases was conducted at 10 European Centres.

 

115 patients between 18 and 74 years diagnosed with chronic spontaneous urticaria, eczema/dermatitis, prurigo or cutaneous pruritus who had not responded to placebo during a run-in period of 7-14 days and with, at least 4 points for the sum of itch score during the last 3 days of the run-in period were included. Patients received bilastine 20 mg once daily for 8 weeks and non-responders (<30% improvement in pruritus score at week 2), received 40 mg daily from week 2.

 

Bilastine reduced the mean change in weekly pruritus severity score from baseline to week 8 (primary endpoint) (overall and by disease group). Up dosed non-responders (n = 31) improved weekly pruritus severity scores from baseline to week 8. Bilastine improved the Dermatology Life Quality Index at weeks 4 and 8 (p < 0,001) in all disease groups, and the 7-day Urticaria Activity Score in CSU patients (p <0 ,001).

 

In conclusion, bilastine has demonstrated efficacy for the relief of pruritus associated with urticaria and other skin diseases in adults, with a very good safety profile. Also, bilastine up dosing to 40mg (double dose), for patients who did not achieve a significant improvement after 2 weeks of treatment, was efficacious without any safety concerns.

This document is only available for registered healthcare professionals.

login
La urticaria crónica (CUR) contribuye a la comprensión y el conocimiento de la enfermedad en la región.

Latin American chronic urticaria registry (CUR) contribution to the understanding and knowledge of the disease in the region

By | Artículos seleccionados, New, Selected articles

Gómez RM, Jares E, Borges MS, Baiardini I, Canonica GW, Passalacqua G, Kaplan A, Latour P, Costa E, Dias G, Lavrut J; SLAAI CUR group.

Chronic urticaria (CU) has a widespread spectrum on causal or exacerbating factors, clinical manifestations, therapeutic response and quality of life affectation. Registries are useful tools in several real-life diagnosis and management approach.We aimed to evaluate the characteristics of CU patients living in Latin America through an original cross-sectional registry with data entered by regional allergologists.

This document is only available for registered healthcare professionals.

login
Diagnosis and treatment of urticaria in primary care

Diagnosis and treatment of urticaria in primary care

By | Artículos seleccionados, New, Selected articles

Kayiran MA, Akdeniz N.

Urticaria, also known as hives among people, is a very common disease characterized by erythematous, edematous, itchy, and transient plaques that involve skin and mucous membranes. It is classified as acute spontaneous urticaria, chronic spontaneous urticaria, chronic inducible urticaria, and episodic chronic urticaria. Many factors such as infections, medicines, food, psychogenic factors, and respiratory allergens are accused of etiology, but sometimes, it is idiopathic. Clinical presentation involves red, swelling, and itchy plaques. The lesions usually resolve spontaneously within 2-3 h without a trace.

This document is only available for registered healthcare professionals.

login
Treatment of urticaria: a clinical and mechanistic approach

Treatment of urticaria: a clinical and mechanistic approach

By | Artículos seleccionados, New, Selected articles

Kaplan AP.

Urticaria can be divided into three general subtypes. Acute urticaria is defined as urticaria of relatively short duration that can be as brief as a day or two or can last up to 6 weeks. “Physical urticarias or inducible urticarias” consist of cold urticaria, cholinergic urticaria, and dermatographism as the most common, plus solar urticaria, local heat urticaria, aquagenic urticaria, vibratory urticaria/angioedema, and delayed pressure urticaria. The third subtype is chronic spontaneous urticaria (CSU) where the urticaria is present for over a minimum of 6 weeks up to many years.

Antihistamines are effective in about 50% of patients with CSU by interacting with the H1 receptor rendering it unresponsive to histamines. Omalizumab is effective in 65–80% of antihistamine-resistant patients and acts by binding IgE, thereby eliminating IgE directed to an autoantigen, downregulating IgE receptors, so that antireceptor antibodies are blocked, and ultimately leading to unresponsiveness of cutaneous mast cells and basophils. The addition of omalizumab represents a major advance because of its efficacy, easy utility, and favourable side-effect profile. Cyclosporine inhibits not only T cells but also histamine release from basophils and mast cells, has a success rate of about 70%, and is recommended third-line with care directed to potential side effects affecting blood pressure and renal function.

In conclusion, the use of antihistamines in high dosage (at least four times a day) is effective in close to half the patients with chronic spontaneous urticaria. For antihistamine resistance, the use of omalizumab has revolutionized therapy of antihistamine-resistant cases because of its efficacy and excellent side-effect profile. If the response is insufficient, cyclosporine is the next choice. Patients should be monitored regarding any adverse effects on blood pressure or renal function. All these are far safer than extended use of corticosteroid.

This document is only available for registered healthcare professionals

Login
Urticaria crónica

Systematic reviews of pharmacological and nonpharmacological treatments for patients with chronic urticaria: An umbrella systematic review

By | Artículos seleccionados, Selected articles

Shi Y, Zhou S, Zheng Q, Huang Y, Hao P, Xu M, Zhang L, Xiao X, Zheng H, Li Y.

A wide range of pharmacological and nonpharmacological interventions for chronic urticaria (CU) have been evaluated in systematic reviews (SRs). We conducted an umbrella review of SRs of the effectiveness and safety of pharmacological and nonpharmacological interventions for CU.

This document is only available for registered healthcare professionals

Login
Terapia de sangrado

Bloodletting Therapy for Patients with Chronic Urticaria: A Systematic Review and Meta-Analysis

By | Artículos seleccionados, Selected articles

Yao Q, Zhang X, Mu Y, Liu Y, An Y, Zhao B.

Many trials have reported that bloodletting therapy is effective when treating chronic urticaria. There are currently no systematic reviews of bloodletting therapy for chronic urticaria.

Bloodletting therapy might be an effective and safe treatment for chronic urticaria, but the evidence is scarce. More high quality trials are needed in the future.

This document is only available for registered healthcare professionals

Login
Urticaria cronica angioedema

Cost-Utility of Routine Testing in Chronic Urticaria/Angioedema: A Cohort Study

By | Artículos seleccionados, Selected articles

Carrillo-Martin I, Dudgeon MG, Chamorro-Pareja N, Haehn DA, Rivera-Valenzuela MG, Spaulding AC, Heckman MG, Diehl NN, Irizarry-Alvarado JM, Helmi H, Gonzalez-Estrada A

Chronic urticaria/angioedema (CUA) guidelines recommend limiting tests to diagnose and assess prognosis, activity, and severity. Routine testing in CUA might substantially increase cost of disease without benefiting outcome.

In CUA, tests rarely uncover underlying conditions or lead to changes in management and outcome, but they substantially increase the costs generated by the disease. Adherence to current recommendations to limit testing might help in reducing the financial burden of CUA and improve delivery of care.

This document is only available for registered healthcare professionals

Login
Urticaria

Eczema and Urticaria in the Adult Population in Portugal: A Prevalence Study

By | Artículos seleccionados, Selected articles

Carvalho D, Aguiar P, Ferrinho P, Mendes-Bastos P, Palma-Carlos A.

A prevalence study was conducted in Portugal to compare the rate of eczema and urticaria within regions and with other countries in Europe.

A telephone interview survey was performed in the last quarter of 2017. Investigators analysed 5000 phone calls to subjects over 16 years old, previously diagnosed with eczema or urticaria living in Portugal. The sample had a proportion representative by population, region, gender and age group.

They estimate the prevalence of eczema and urticaria in Portugal is 4,4 and 3,4%, respectively. Algarve is the region with the highest prevalence. Women are also more affected than men are and seem to be more at risk than men.

Overall, the prevalences found are higher than previously reported, but comparable to results from other countries. From a former study by Harrop and his team, in Europe atopic eczema is 0,14-0,60% of general eczema. Portuguese investigators estimate that atopic eczema prevalence in Portugal is around 0,61-2,64%.

This document is only available for registered healthcare professionals

Login
bilastina alivia prurito

Efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases: an exploratory study

By | Articles about Bilastine, New

Serra E, Campo C, Novák Z, Majorek-Olechowska B, Pulka G, García-Bea A, Labeaga L.

PURPOSE: To evaluate the efficacy/safety of bilastine in pruritus relief in patients with chronic spontaneous urticaria (CSU) or other pruritic skin diseases.

CONCLUSIONS: Bilastine relieved pruritus associated with urticaria and other skin diseases, with a very good safety profile.

This document is only available for registered healthcare professionals

Login
Bilastina y anticuerpos anti-

Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America

By | Selected articles
Ivan Cherrez-Ojeda, et al. World Allergy Organization Journal

A retrospective, observational study assessed 72 Latin American patients with chronic urticaria treated with omalizumab to evaluate patient-reported outcomes in management of their disease, as well as omalizumab effectiveness and treatment patterns in real-life setting.

Updated urticaria guidelines recommend that patients should be assessed for disease activity, severity, control and quality of life at baseline and follow-up.

Omalizumab is a guideline-recommended second-line alternative anti-IgE monoclonal antibody in case of antihistamine refractoriness. It has been shown to be effective in patients with chronic autoimmune urticaria who were symptomatic despite antihistamine therapy.

From the 72 participants, 44 (80,0%) responded to omalizumab at some point of the treatment. Omalizumab 300 mg was associated with earlier response compared to lower doses. Regardless of dosage, most participants improved quality of life. Fifteen participants interrupted omalizumab before the third month of treatment

In conclusion, most patients responded to the treatment and improved their quality of life at a lower dose than the 300 mg recommended by the guidelines and clinical trials.

This document is only available for registered healthcare professionals.

Acceder

La información que está a punto de visualizar está dirigida únicamente a los profesionales sanitarios aptos para prescribir o dispensar medicamentos. La correcta utilización de su contenido requiere de formación como profesional sanitario.

Debe hacer clic en Aceptar para confirmar que es usted profesional de la salud y continuar con la navegación.

ACEPTAR